According to a report issued by the HHS Office of Inspector General, FDA generally spent prescription drug user fee collections appropriately. The review found the lack of supporting documentation for a few travel expenses, which appeared to be an oversight by FDA staff and not a systemic issue.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
